Integer Holdings Corporation
https://www.integer.net/home/default.aspx
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Integer Holdings Corporation
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
Organs On Chips: The Primer Is Ready, But The Bullet Will Take Time To Fire
In the first part of this two-part series, In Vivo discussed the potential for organs on chips to revolutionize drug development. However, great challenges wait for developers of the technology.
Deal Watch: Roche, PhoreMost Enter Into Multi-Target Collaboration
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
Dealmaking Quarterly Statistics, Q2 2022
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
Company Information
- Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Aran Biomedical Ltd.
- CCC Medical Devices
- Greatbatch, Inc.
- InoMec Ltd.
- Lake Region Medical Holdings, Inc.
- NeuroNexus Technologies
- Oscor, Inc.
- Quan Emerteq LLC
- US BioDesign, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice